Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Novartis is hoping that Scemblix (asciminib) will become the physician’s first choice of therapy for chronic myeloid ...

The global immuno-oncology market is set to witness a growth rate of 21% in the next 5 years. Increasing incidence and ...

Shiva Malek highlights her work on cancer cell signaling and the importance of new spatial tools in understanding the bigger ...

Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer: Basel Tuesday, June 3, 2025, 18:00 Hrs [IST] Novarti ...

More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as ...